BTCC
/
BTCC Square
/
Global Cryptocurrency
/
BeyondSpring’s Plinabulin Data Spurs 5.28% Stock Surge on NSCLC Breakthrough
BeyondSpring’s Plinabulin Data Spurs 5.28% Stock Surge on NSCLC Breakthrough
14
1
BTCCSquare news:
BeyondSpring Inc. (BYSI) shares rallied 5.28% to $2.1150 after presenting Phase 3 trial results at ESMO Asia 2025. The DUBLIN-3 study demonstrated Plinabulin’s statistically significant survival benefit in EGFR wild-type NSCLC patients, with a median overall survival of 10.8 months versus 8.8 months for docetaxel alone (HR 0.81, p=0.0426).
The data strengthens the case for global regulatory submissions. Market response reflects Optimism about Plinabulin’s potential to address unmet needs in second- and third-line NSCLC treatment. The combination therapy’s performance in Asian patient subsets was particularly noteworthy.
By:
